SEARCH

SEARCH BY CITATION

References

  • ASSMANN, B. & HAAS, H.J. (1990). Determination of creatinine-related urinary uracil excretion in children by high-performance liquid chromatography. J. Chromatogr., 525, 277285.
  • BARRAT, M.A., RENEE, N., MORMONT, M.C., MILANO, G. & LEVI, F. (2003). Circadian variations of dihydropyrimidine dehydrogenase (DPD) activity in oral mucosa of healthy volunteers. Pathol. Biol. (Paris), 51, 191193.
  • BEUZEBOC, P., PIERGA, J.Y., LYONNET, D.S., COUTURIER, J. & POUILLAR, P. (1996). Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency. Bull. Cancer, 83, 324327.
  • BI, D., ANDERSON, L.W., SHAPIRO, J., SHAPIRO, A., GREM, J.L. & TAKIMOTO, C.H. (2000). Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase. J. Chromatogr. B, 738, 249258.
  • CHAU, I., CHAN, S. & CUNNINGHAM, D. (2003). Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives. Clin. Colorectal Cancer, 3, 1933.
  • CHAZAL, M., ETIENNE, M.C., RENEE, N., BOURGEON, A., RICHELME, H. & MILANO, G. (1996). Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin. Cancer Res., 2, 507510.
  • DELVAL, L. & KLASTERSKY, J. (2002). Optic neuropathy in cancer patients. Report of a case possibly related to 5 fluorouracil toxicity and review of the literature. J. Neurooncol., 60, 165169.
  • ETIENNE, M.C., LAGRANGE, J.L., DASSONVILLE, O., FLEMING, R., THYSS, A., RWNEE, N., SCHNEIDER, M., DEMARD, F. & MILANO, G. (1994). Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol., 12, 22482253.
  • GAMELIN, E., BOISDRON-CELLE, M., GUERIN-MEYER, V., DELVA, R., LORTHOLARY, A., GENEVIEVE, F., LARRA, F., IFRAH, N. & ROBERT, J. (1999). Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J. Clin. Oncol., 17, 11051110.
  • GREM, J.L., YEE, L.K., VENZON, D.J., TAKIMOTO, C.H. & ALLEGRA, C.J. (1997). Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother. Pharmacol., 40, 117125.
  • HALBERG, F., JOHNSON, E.A., NELSON, W., RUNGE, W. & SOUTHERN, R. (1972). Autorhythmometry procedures for physiologic self-measurements and their analysis. Physiol. Teacher, 1, 111.
  • HARRIS, B.E., SONG, R., SOONG, S.J. & DIASIO, R.B. (1990). Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res., 50, 197201.
  • HARRIS, B.E., SONG, R.L., HE, Y.J., SOONG, S.J. & DIASIO, R.B. (1988). Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. Biochem. Pharmacol., 37, 47594762.
  • HEGGIE, G.D., SOMMADOSSI, J.P., CROSS, D.S., HUSTER, W.J. & DIASIO, R.B. (1987). Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 47, 22032206.
  • JIANG, H., JIANG, J., HU, P. & HU, Y.F. (2002). Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B, 769, 169176.
  • LAKIN-THOMAS, P.L. (2000). Circadian rhythms: new functions for old clock genes. Trends Genet., 16, 135142.
  • LU, Z., ZHANG, R., CARPENTER, J.T. & DIASIO, R.B. (1998). Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin. Cancer Res., 4, 325329.
  • LU, Z., ZHANG, R. & DIASIO, R.B. (1993). Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res., 53, 54335438.
  • MACDONALD, J.S. (1999). Toxicity of 5-fluorouracil. Oncology (Huntington), 13 (Suppl 3), 3334.
  • MARTIN, M., VILLAR, A., SOLE-CALVO, A., GONZALEZ, R., MASSUTI, B., LIZON, J., CAMPS, C., CARRATO, A., CASADO, A., CANDEL, M.T., ALBANELL, J., ARANDA, J., MUNARRIZ, B., CAMPBELL, J. & DIAZ-RUBIO, E. (2003). Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann. Oncol., 14, 833842.
  • MILANO, G. & CHAMOREY, A.L. (2002). Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol. Int., 19, 177189.
  • MILANO, G. & ETIENNE, M.C. (1996). Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. Ther. Drug Monit., 18, 335340.
  • MILANO, G., ETIENNE, M.C., PIERREFITE, V., BARBERI-HEYOB, M., DEPORTE-FETY, R. & RENEE, N. (1999). Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br. J. Cancer, 79, 627630.
  • MILANO, G. & MCLEOD, H.L. (2000). Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment Eur. J. Cancer, 36, 3742.
  • NAGUIB, F.N., EL KOUNI, M.H. & CHA, S. (1985). Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res., 45, 54055412.
  • PORSIN, B., FORMENTO, J.L., FILIPSKI, E., ETIENNE, M.C., FRANCOUAL, M., RENEE, N., MAGNE, N., LEVI, F. & MILANO, G. (2003). Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression. Eur. J. Cancer, 39, 822828.
  • SINGH, B., LI, R., XU, L., POLURI, A., PATEL, S., SHAHA, A.R., PFISTER, D., SHERMAN, E., GOBERDHAN, A., HOFFMAN, R.M. & SHAH, J. (2002). Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck, 24, 437442.
  • VAN KUILENBURG, A.B., DE ABREU, R.A. & VAN GENNIP, A.H. (2003). Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann. Clin. Biochem., 40, 4145.
  • YINGNA, S., YANG, X., XIUYU, Y. & HONGZHAO, S. (2002). Clinical characteristics and treatment of gestational trophoblastic tumor with vaginal metastasis. Gynecol. Oncol., 84, 416419.
  • ZHANG, R., LU, Z., LIU, T., SOONG, S.J. & DIASIO, R.B. (1993). Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res., 53, 28162822.